A survey of patient and caregiver experience with malignant pleural mesothelioma

被引:27
|
作者
Warby, Anne [1 ,2 ]
Dhillon, Haryana M. [1 ]
Kao, Steven [2 ,3 ,4 ]
Vardy, Janette L. [1 ,2 ,4 ,5 ]
机构
[1] Univ Sydney, Ctr Med Psychol & Evidence Based Decis Making, Sydney, NSW 2006, Australia
[2] Bernie Banton Ctr, Asbestos Dis Res Inst, Gate 3,Hosp Rd, Concord, NSW 2139, Australia
[3] Chris OBrien Lifehouse, 119-143 Missenden Rd, Camperdown, NSW 2050, Australia
[4] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
[5] Concord Repatriat Gen Hosp, Concord Canc Ctr, Hosp Rd, Concord, NSW 2139, Australia
关键词
Malignant pleural mesothelioma; Patient experience; Caregivers; Decision-making; Chemotherapy; PALLIATIVE CARE; DECISION REGRET; EUROPEAN-ORGANIZATION; FAMILY CAREGIVERS; PHASE-III; CHEMOTHERAPY; CISPLATIN; ANXIETY; RISK;
D O I
10.1007/s00520-019-04760-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Malignant pleural mesothelioma (MPM) is a rare cancer with poor prognosis. As there is little information on the lived experience of MPM, our aim was to document the experience of MPM patients and their caregivers. Methods Surveys for MPM patients and caregivers were developed from previous interviews with patients, caregivers, and health professionals, about treatments and decision-making. Participants were recruited from two hospitals, government compensation body, and support groups. Results Survey responses were received from 78 MPM patients and 106 caregivers from January to September 2014. Patients: 85% male, median age 69 years, median time since diagnosis 15 months. Caregivers: median age 68, 91% female, 90% spouse of MPM patient, 95% bereaved. Most participants felt informed about treatment options but only 69% thought all treatment options were discussed. Chemotherapy was discussed most frequently (92-95%); similar to 80% had sufficient information for decision-making. Decision regarding chemotherapy was made by patient considering doctor's opinion (24%), doctor and patient equally (18%), and doctor (17%). Participants 'agreed'/'strongly agreed' that they made the right decision about chemotherapy (patients 81%, caregivers 60%), but 5% and 16%, respectively, regretted the decision. Most participants received 'sufficient' support (71%). A quarter reported seeing cancer nurse specialists. Palliative care referral: 31% patients, 85% caregivers. Caregivers would have liked to talk to someone by themselves (41%), more time with doctors (30%), psychological support (29%), and clearer information (31%). Bereaved caregivers requested grief counselling (39%) and post-death consultation with specialists (23-25%). Conclusions Satisfaction with treatment was high, but participants identified need for improved communication and quality information, discussion about all treatments, end-of-life assistance, and caregiver support after the patient's death.
引用
收藏
页码:4675 / 4686
页数:12
相关论文
共 50 条
  • [41] Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
    Zhang, Dandan
    Liang, Jianping
    Lv, Yanhua
    Huang, Xikun
    Guo, Weihong
    MEDICINE, 2022, 101 (52) : E32459
  • [42] Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma
    Karatkevich, Darya
    Deng, Haibin
    Gao, Yanyun
    Flint, Emilio
    Peng, Ren-Wang
    Schmid, Ralph Alexander
    Dorn, Patrick
    Marti, Thomas Michael
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (19)
  • [43] Malignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient
    Wald, Ori
    Sugarbaker, David J.
    JOURNAL OF THORACIC DISEASE, 2017, 9 (03) : 485 - 489
  • [44] A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index
    Kataoka, Yuki
    Yamamoto, Yosuke
    Otsuki, Taiichiro
    Shinomiya, Mariko
    Terada, Takayuki
    Fukuma, Shingo
    Yamazaki, Shin
    Hirabayashi, Masataka
    Nakano, Takashi
    Fukuhara, Shunichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (06) : 562 - 568
  • [45] Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma
    Zucali, P. A.
    Perrino, M.
    Lorenzi, E.
    Ceresoli, G. L.
    De Vincenzo, F.
    Simonelli, M.
    Gianoncelli, L.
    De Sanctis, R.
    Giordano, L.
    Santoro, A.
    LUNG CANCER, 2014, 84 (03) : 265 - 270
  • [46] Malignant pleural mesothelioma: A retrospective analysis of clinicopathological and survival data
    Adel, Azza M.
    Hafeez, Zeinab M. Abdel
    El Sheikh, Eman T.
    El Sharawy, Iman A.
    Gobran, Nagy S.
    THORACIC CANCER, 2011, 2 (01) : 16 - 23
  • [47] Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey
    Zucali, P. A.
    Simonelli, M.
    Michetti, G.
    Tiseo, M.
    Ceresoli, G. L.
    Collova, E.
    Follador, A.
    Lo Dico, M.
    Moretti, A.
    De Vincenzo, F.
    Lorenzi, E.
    Perrino, M.
    Giordano, L.
    Farina, G.
    Santoro, A.
    Garassino, M.
    LUNG CANCER, 2012, 75 (03) : 360 - 367
  • [48] Immunotherapy in malignant pleural mesothelioma: a long story ended in success
    Bongiovanni, Alberto
    Frassoldati, Antonio
    Calabro, Luana
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2022, 8
  • [49] Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma
    Yao, Zhou-Hong
    Tian, Guang-Yan
    Wan, Yun-Yan
    Kang, Yan-Meng
    Guo, Hai-Sheng
    Liu, Qing-Hua
    Lin, Dian-Jie
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (12) : 2117 - 2123
  • [50] Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group
    Remon, J.
    Nadal, E.
    Domine, M.
    Ruffinelli, J.
    Garcia, Y.
    Pardo, J. C.
    Lopez, R.
    Cilleruelo, A.
    Garcia-Campelo, R.
    Martin, P.
    Juan, O.
    Gonzalez-Larriba, J. L.
    Provencio, M.
    Olmedo, E.
    Ponce, S.
    Cumplido, D.
    Barenys, C.
    Majem, M.
    Massutti, B.
    Rodriguez-Abreu, D.
    Porta, R.
    Sala, M. A.
    Martinez-Kareaga, M.
    Lianes, P.
    Reguart, N.
    LUNG CANCER, 2020, 147 : 83 - 90